Impact Of Sacubitril/Valsartan Treatment On Depression And Anxiety In Heart Failure With Ischemic Cardiomyopathy

Objectives The purpose of this study was to investigate the impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with ischemic cardiomyopathy.Methods Two hundred patients with ischemic cardiomyopathy complicated with heart failure,who were admitted to the Department of Cardiology,Tangshan Gongren Hospital from April 2019 to July 2020,were randomly divided into enalapril group(ACEI group,n=93)and sacubitril/valsartan group(ARNI group,n=95).We analyze the changes in left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),left ventricular mass index(LVMI),Nterminal pro-brain natriuretic peptide(NT-pro BNP),Kansas City cardiomyopathy questionnaire(KCCQ)score,hypersensitive C-reactive protein(hs-CRP),6-minute walking distance(6-MWD),Beck depression inventory-II(BDI-II)score,Beck Anxiety Inventory(BAI)score after 6 months of treatment in the two groups.Results 1 There were no significant differences in LVEF,LVESD,LVEDD,LVMI,NTpro BNP,KCCQ score,hs-CRP,6-MWD,BDI-II score and BAI score between the two groups before treatment(P>0.05);2 After 6 months of treatment,the LVEF,KCCQ score and 6-MWD in the two groups were higher than those before treatment,while the scores of LVESD,LVEDD,LVMI,NT-pro BNP and hs-CRP in the two groups were significantly lower than those before treatment,and the improvement in the ARNI group was more obvious than that in the ACEI group(P<0.05);3 After 6 months treatment,the scores of BDI-II and BAI were lower than those before treatment,and the difference was statistically significant(P<0.05).The scores of BDI-II and BAI in ACEI group after treatment had no significant difference from those before treatment(P>0.05);4 There was no significant difference in the incidence of adverse events between the two groups after 6 months of treatment.(P>0.05).Conclusions Compared with enalapril,sacubitril/valsartan can effectively improve the state of depression and anxiety,cardiac function and the quality of life in patients with heart failure in ischemic cardiomyopathy.Figure 2;Table 9;Reference 142...